# Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

> **NCT00148837** · PHASE2 · UNKNOWN · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 112 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Fibrosis

## Interventions

- **DRUG:** Peg-interferon alpha 2b (drug)
- **DRUG:** Ribavirin (drug)
- **DRUG:** Prazosin (drug)

## Key facts

- **NCT ID:** NCT00148837
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2008-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148837, "Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00148837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*